home / stock / rvv:cc / rvv:cc news

RVV:CC News and Press, Revive Therapeutics Ltd - Ordinary Shares From 06/12/24

Stock Information
Company Name: Revive Therapeutics Ltd - Ordinary Shares
Stock Symbol: RVV:CC
Market: CNQC
Website: revivethera.com
Menu
RVV:CC RVV:CC Quote RVV:CC Short RVV:CC News RVV:CC Articles RVV:CC Message Board
Get RVV:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
RVV:CC - Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID

TORONTO, June 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases,...
RVV:CC - Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product

TORONTO, June 10, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases,...

RVV:CC - Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID

TORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases...

RVV:CC - Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product

TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious disease...
RVV:CC - Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID

TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, a...

RVV:CC - Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID

TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, a...

RVV:CC - Revive Therapeutics Provides Corporate Update

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, a...
RVV:CC - Expected Canadian Company Earnings on Tuesday, February 27th, 2024

Mirasol Resources Ltd. (MRZ:CA) is expected to report for quarter end 2023-12-31 Empower Clinics Inc. (EPW:CNX) is expected to report for quarter end 2023-12-31 BluMetric Environmental Inc. (BLM:CA) is expected to report for quarter end 2023-12-31 GoldMining Inc. (GOLD:CA) is expected...

RVV:CC - Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. ( CSE: RVV; OTCQB: RVVTF ) (“ Revive ” or the ...

RVV:CC - Revive Therapeutics Explores the Use of Bucillamine for Long COVID

TORONTO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, an...
Previous 10 Next 10